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Abstract
Background: Fibroblast growth factor 23 (FGF23) is a phosphaturic hormone that is
increased in azotemic cats with chronic kidney disease (CKD) and predictive of the
onset of azotemia in older cats. The introduction of symmetric dimethylarginine
(SDMA) as a biomarker of glomerular filtration rate has led to the identification of
cats in which SDMA is increased, but plasma creatinine concentrations remains
within reference range. There is currently little understanding of the metabolic
changes present in such cats.
Objectives: To examine the relationship between plasma FGF23 and SDMA concen-
trations in non-azotemic geriatric cats.
Animals: Records of a cross section of client-owned cats (n = 143) without azotemic CKD.
Methods: Clinicopathological information was obtained from cats (≥ 9 years) from
records of 2 first opinion practices. The relationship between plasma SDMA and
FGF23 concentrations was examined using Spearman's correlation and variables
compared using the Mann-Whitney U test.
Results: Cats with increased SDMA concentrations had significantly higher plasma
FGF23 (P < .001) and creatinine (P < .001) concentrations compared to cats with
SDMA concentrations within reference range. A weak positive relationship was dem-
onstrated between plasma FGF23 and SDMA concentrations (r = .35, P < .001) and
between plasma FGF23 and creatinine (r = .23, P = .005) concentrations.
Conclusions and Clinical Importance: More cats with increased SDMA concentrations
had higher FGF23 concentrations than those with SDMA concentrations within the ref-
erence range, suggesting the presence of an alteration in phosphate homeostasis. Fur-
ther studies are warranted to identify influencing factors and to explore the utility of
FGF23 concentration to informmanagement of cats with early stage CKD.
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1 | INTRODUCTION
Symmetric dimethylarginine (SDMA), a methylarginine produced in the
nucleus of all cells,1 is cleared primarily by the kidneys. Plasma SDMA
concentration has been shown to have a strong negative correlation
with glomerular filtration rate (GFR) and a strong positive correlation
with plasma creatinine concentration in both humans and cats,1-3
highlighting its suitability as a renal biomarker. Importantly, in a popula-
tion of geriatric cats with naturally occurring chronic kidney disease
(CKD), plasma SDMA concentration has been shown to increase an
average of 17 months before an increase in plasma creatinine concen-
tration above its upper reference range.4 In recent years, International
Research Interest Society (IRIS) guidelines5 have been modified to
include a persistent increase in SDMA concentration above reference
range, with a plasma creatinine concentration of <1.6 mg/dL
(140 μmol/L) in cats as a criterion for classification of IRIS Stage 1 CKD
and indicative of decreased renal function.
Fibroblast growth factor 23 (FGF23) is a key regulatory hormone in
phosphate homeostasis. Consisting of 251 amino acids, it is secreted by
osteoblasts and osteocytes and binds to fibroblast growth factor recep-
tors (FGFR), specifically FGFR1c, which is widely expressed throughout
the body.6 Within renal tubular epithelial cells, FGF23-Klotho-FGFR1c
initiates mitogen-activated protein kinase, extracellular signal-related
kinase-1/2, or early growth response-1 pathways.7 These signals act to
downregulate expression of NaPi2a cotransporters resulting in
decreased reabsorption of phosphate and increased phosphaturia.
In CKD, a decrease in GFR and subsequent increase in serum phos-
phate concentration cause a disruption in phosphate-calcium homeosta-
sis.8 Chronic kidney disease-mineral and bone disorder (CKD-MBD)
describes a syndrome observed in humans with CKD involving derange-
ments in blood concentrations of FGF23, parathyroid hormone (PTH),1,
25-dihydroxyvitamin D3 (1,25 vitamin D3, calcitriol), calcium and phos-
phate, with accompanying renal osteodystrophy and vascular and soft
tissue calcification.9 In humans with CKD-MBD, it is well established
that an increase in serum FGF23 concentration precedes an increase in
serum phosphate concentration.10 Furthermore, in all stages, including
early stage CKD, the prevalence of FGF23 excess has been shown to be
higher than that of other hormonal derangements, suggesting that iden-
tification of FGF23 excess may be the earliest indicator of an adaptive
mechanism for deranged phosphate homeostasis in CKD.10
In cats with CKD, the same mineral and hormone derangements
occur. Fibroblast growth factor 23 and PTH have been shown to be
increased despite normal plasma total calcium (tCa) and phosphorus
concentrations in cats that develop azotemic CKD compared to those
that remain non-azotemic, suggesting the presence of altered phos-
phate homeostasis11,12 in early stage non-azotemic CKD. No publi-
shed studies have examined the metabolic status of non-azotemic
cats with increased SDMA, which may be considered to have early
stage CKD.
Our aim was to examine the relationship between plasma FGF23
and SDMA concentrations in geriatric non-azotemic cats.
2 | METHODS
2.1 | Case selection
Records from a geriatric cat clinic held at 2 London-based first opinion
practices (Beaumont Sainsbury Animal Hospital in Camden and People's
Dispensary for Sick Animals in Bow) between October 2011 and
December 2016 were reviewed and cases were retrospectively selected.
The clinic prospectively recruits apparently healthy cats >9 years of age
for wellness screening and longitudinal monitoring every 6 months, spe-
cifically to evaluate for the development of systemic hypertension, CKD
hyperthyroidism, or some combination of these.
Records of cats that were azotemic or had a history of azotemia,
plasma total thyroxine (TT4) concentration > 40 nmol/L (reference
range, 10-55 nmol/L), received medical treatment for hyperthyroidism,
or had diabetes mellitus were excluded from the analysis. Cats receiving
treatment for systemic hypertension with amlodipine besylate were
included. Cats were included in the analysis if they had plasma FGF23
or SDMA concentration recorded and sufficient stored sample to mea-
sure required variables that had not been quantified previously. In cats
that had been evaluated at the clinic multiple times during the study
period, only the first recorded visit was included in the analysis.
The following historical, physical examination findings and biochemi-
cal data were required and extracted from the records: plasma creatinine,
urea, phosphate, tCa, total magnesium (tMg), TT4, SDMA, FGF23 and
PTH concentrations, packed cell volume (PCV), urine specific gravity, age,
weight, body condition score, muscle condition score,13 breed, and sex.
2.2 | Blood and urine sampling
All cats initially were examined and samples collected and stored under
the approval of the Ethics andWelfare Committee of the Royal Veterinary
College and with informed consent of the owner. Blood samples had
been obtained by jugular venipuncture and transferred to ethylene-
diaminetetraacetic acid (EDTA) and heparinized tubes. Urine sampleswere
collected by cystocentesis. According to clinic protocol for sample
processing, samples were stored at 4C after collection, for a maximum of
6 hours before centrifugation and separation. Heparinized plasma was
submitted to an external laboratory (IDEXX laboratories, Wetherby,
United Kingdom) for biochemical analysis on the day of sample collection.
Residual heparinized and EDTA plasma samples were stored at−80C for
future batch analysis. Where measurement had not already been per-
formed, EDTA plasma samples were used tomeasure PTH concentrations
using a total intact PTH immunoradiometric assay previously validated for
cats (Total intact PTH immunoradiometric assay-coated bead version,
3KG600, Scantibodies, Santee, California).14 The lower limit of detection
of the assaywas determined to be 5.2 pg/mL. Therefore, any sampleswith
PTH concentration <5.2 pg/mL were arbitrarily assigned a value of
2.6 pg/mL. Intact plasma FGF23 concentrationwasmeasured using EDTA
plasma samples using a previously validated enzyme-linked immunosor-
bent assay (ELISA; FGF23 ELISA Kit, Kainos Laboratories, Tokyo, Japan).15
Stored heparin plasma samples were sent to an external laboratory for
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SDMAquantification. Urine specific gravitywas determined by refractom-
etry on urine samples on the day of collection.
2.3 | Statistical analysis
Statistical analyses were performed using commercial software (IBM
SPSS Statistics for Windows, Version 24, IBM, Corp, Armonk,
New York; GraphPad Prism 7, GraphPad Software, La Jolla, California).
Statistical significance was set at P < .05. Normality of the numerical
data distribution was assessed by visual inspection of histograms. The
majority of data was not normally distributed and for consistency all
numerical clinical data is presented as median (25th and 75th percen-
tiles). Cats were grouped into those with SDMA concentration above
reference range (>14 μg/dL) and those with SDMA within reference
interval (≤14 μg/dL).16 Comparisons were made between groups using
Mann-Whitney U tests and relationships between numerical variables
were evaluated using Spearman's correlation.
3 | RESULTS
Between October 2011 and December 2016, 876 non-azotaemic cats
were identified, of which 422 were excluded because of suspected or
documented hyperthyroidism and 11 because of documented histori-
cal azotemia. Of the remaining 443 cats, 300 did not have recorded
either a plasma FGF23 or SDMA concentration or had insufficient
stored EDTA or heparin plasma sample available for measurement of
either plasma FGF23 or SDMA.
The study population consisted of 143 cats; 76 females (3 intact)
and 67 males (1 intact). Most common breeds were domestic short hair
(n = 109) and domestic long hair (n = 23), Birman (n = 2), Siamese (n = 2),
British Short Hair (n = 2), and 1 each of Birman cross, Devon Rex, Per-
sian, Norwegian Forest, and Burmese. Eighty cats had plasma SDMA
concentration measured at the time of sampling; the remaining 63 cats
had SDMA measured on stored heparin plasma within 70 months of
sample collection. All 143 cats had plasma FGF23 and PTH concentra-
tions measured on stored EDTA plasma within 18 months of sample
date. Of the 143 cats, 107 had plasma SDMA concentrations within the
reference range (≤14 μg/dL) and 36 had increased plasma SDMA con-
centrations. Clinicopathological variables for each group are found in
Table 1.
Outliers were identified: 1 cat with plasma SDMA concentration of
63 μg/dL and 3 cats with plasma FGF23 concentrations of 1345, 1502,
and 1300 pg/mL. Analysis was repeated without outliers; results did not
differ. All stated P values are for the whole cohort, including outliers.
A significant weak positive correlation was found between plasma
FGF23 and SDMA concentrations (r = .353; P < .001; Figure 1). A signifi-
cant moderate positive correlation was found between plasma creatinine
and SDMA concentrations (r = .525; P < .001; Figure 2). A significant
weak positive correlation was found between plasma FGF23 and creati-
nine concentrations (r = .232, P = .005; Figure 3). No significant correla-
tion was found between plasma FGF23 and phosphate concentrations
(P = .22) or plasma FGF23 and tMg concentrations (P = .60).
Plasma FGF23 concentrations and plasma creatinine concentra-
tions were significantly higher in cats with plasma SDMA concentra-
tions above the reference range (>14 μg/dL; P < .001; Figure 4). No
other significant differences in clinicopathological variables between
SDMA groups were observed (Table 1 and Figure 4).
4 | DISCUSSION
Results of our retrospective study show that more cats with plasma
SDMA concentration above the reference range had significantly
higher plasma FGF23 and creatinine concentrations than did cats with
plasma SDMA concentration within reference interval, with no signifi-
cant difference in plasma phosphate, tCa or PTH concentrations
between groups. We also identified a positive correlation between
plasma FGF23 and both plasma SDMA and creatinine concentrations
and a strong positive correlation between plasma SDMA and plasma
creatinine concentration. The strength of these correlations is likely to
have been influenced by the limited range of stages of CKD included
in the study, because the intent was to evaluate early IRIS stage CKD.
Plasma SDMA and creatinine concentrations are established indi-
rect biomarkers of GFR,2,17 and the positive correlation observed in
our study reflects previous studies. The retrospective nature of our
study meant that GFR measurement was not performed, but the sig-
nificantly higher plasma creatinine concentration in those cats with
increased plasma SDMA concentrations compared to those with
SDMA concentrations within the reference range is supportive of an
early decrease in GFR in these cats. Although, it should be recognized
that a limitation of this study is the single plasma SDMA concentra-
tion used to classify cats, IRIS recommendations specify a persistent
increase in SDMA on ≥2 occasions to be used in clinical practice.5 The
weak positive relationship of plasma FGF23 concentration with both
plasma creatinine and SDMA concentrations was expected, given that
SDMA and creatinine are established indirect biomarkers of GFR and
plasma FGF23 concentration is known to increase with decreasing
GFR.18 However, evidence exists that GFR is not the only factor
influencing FGF23 concentrations.
In human medicine, it has been well established that plasma FGF23
concentration increases in patients with CKD and that increases in plasma
FGF23 and PTH concentrations occur before hyperphosphatemia.10,18,19
A cross-sectional study of nearly 3879 CKD patients10 indicated the prev-
alence of increased FGF23 concentration was higher than that of
increased PTH concentration across all levels of estimated GFR (eGFR),
including those patients with the most preserved eGFR, and it has been
suggested that increased plasma FGF23 concentration is the earliest indi-
cator of a disordered mineral metabolism in CKD. The most striking result
of our study was the significantly higher plasma FGF23 concentration
despite no significant difference in plasma phosphate or PTH concentra-
tions in catswith increased plasma SDMAconcentrations.
Previous studies of client-owned cats >9 years of age have shown
increases in both plasma FGF23 and PTH concentrations to be predic-
tive of the onset of azotemia.11,12 Interestingly, in another study,10 the
proportion of patients with increased plasma FGF23 concentrations and
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normal PTH concentrations was significantly higher than the proportion
of patients with increased PTH concentrations only across all stages of
CKD, reflecting our findings that plasma PTH concentration was not sig-
nificantly different in those cats with increased plasma SDMA concen-
tration compared to those with plasma SDMA concentration within
reference range and considered to have normal renal function. How-
ever, it also should be recognized that in our study, plasma PTH concen-
trations were available in only 38% of cases with increased plasma
SDMA concentrations, which may have led to insufficient statistical
power to identify a significant difference between groups. Interestingly,
a recent meta-analysis of 611 studies examining the relationship among
eGFR, plasma FGF23, and soluble α-klotho concentrations in patients
with CKD observed a significant positive correlation between eGFR and
soluble α-klotho and a significant negative correlation between soluble
α-klotho and FGF23 concentrations.20 Significant negative correlation
between plasma soluble α-klotho and FGF23, phosphate, and PTH con-
centrations in CKD patients also has been identified.21 Soluble α-klotho,
the functional circulating form of the transmembrane bound coreceptor
for FGF23, may be an early biomarker for a decrease in GFR and also a
marker for CKD-MBD.21 The relationship of plasma soluble α-klotho
concentration with both GFR and CKD-MBD has not yet been studied
in cats with CKD.
Multiple mechanisms for an increase in plasma FGF23 concentration
in early CKD have been proposed, principally as an adaptive mechanism
TABLE 1 Clinicopathological characteristics of cats grouped according to SDMA status
SDMA within RI (n = 107) n SDMA above RI (n = 36) n P value
SDMA (1-14 μg/dL) 10 [10, 11] 107 15 [15, 19] 36
Age (years) 12.2 [11.2, 14.5] 107 14 [12.1, 15.3] 36 .66
Weight (kg) 4.35 [3.36, 5.08] 107 4.01 [3.02, 4.85] 36 .22
BCS (1-9) 5 [4, 6] 107 5 [3, 5] 36 .19
MCS (0-2) 1 [1, 2] 105 1 [1, 1] 36 .06
Sex (male n [%]) 40 107 54 36 .25
PCV (%) 38 [25, 40] 106 35 [33, 40] 36 .12
Creatinine (0.23-2.00 mg/dL) 1.49 [1.31, 1.67] 107 1.76 [1.59, 1.89] 36 <.001
FGF23 (56-700) pg/mL) 155 [127, 243] 107 271 [176, 523] 36 <.001
PTH (2.6-17.6 pg/mL) 7 [2.6, 11.3] 44 7.3 [4.1, 9.3] 10 .84
Phosphate (2.71-6.89 mg/dL) 3.66 [3.22, 4.12] 107 3.84 [3.28, 4.18] 36 .40
Total calcium (8.22-11.82 mg/dL) 9.7 [9.3, 10.1] 107 9.98 [9.5, 10.18] 36 .70
Total magnesium (1.73-2.57 mg/dL) 2.14 [2.04, 2.26] 36 1.97 [1.87, 2.21] 5 .62
Note: Data presented as median [25th, 75th percentile] or prevalence (n [%]).
Abbreviations: BCS, body condition score; FGF23, fibroblast growth factor 23; MCS, muscle condition score; PCV, packed cell volume; PTH, parathyroid
hormone; RI, reference interval; SDMA, symmetric dimethylarginine.
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F IGURE 1 Scatter plot illustrating the relationship between
plasma symmetric dimethylarginine (SDMA) and plasma fibroblast
growth factor 23 (FGF23) concentration. The broken lines represent
upper reference interval for plasma SDMA16 (14 μg/dL) and plasma
FGF2315 (700 pg/mL) concentrations. Outliers have been omitted
from the graph
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F IGURE 2 Scatter plot illustrating the relationship between
plasma symmetric dimethylarginine (SDMA) and plasma creatinine
concentration. The broken line represents the upper reference
interval for plasma SDMA16 concentration (14 μg/dL). Outliers have
been omitted from the graph
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to disturbed phosphate homeostasis and as a result of decreased renal
clearance.19,22,23 A strong inverse correlation between GFR and circulat-
ing FGF23 concentration has been established in humans18 and reported
in cats.12 However, a number of studies have shown increased bone
expression of FGF23 in all stages of CKD including early stages and also
in acute kidney injury (AKI), supporting the hypothesis that increased
plasma FGF23 concentration in early CKD is primarily caused by
increased secretion rather than solely a decrease in renal clearance. In a
study of 32 human patients with CKD Stages 2 to 5, immunohistochemi-
cal analysis of biopsy samples from the iliac crest identified increased
FGF23 expression in early CKD which was shown to correlate positively
with plasma FGF23 concentration (r = .43, P < .01).24 Interestingly, in
2 animal models of toxin-induced AKI,25 in which plasma FGF23 concen-
trations were shown to increase rapidly, immunohistochemical and
Western blot analysis of femoral bone indicated that bone concentra-
tions of FGF23 were 2-fold higher than in controls. Furthermore, in the
same model, the half-life of recombinant human FGF23 administered IV
was only modestly increased in mice with AKI compared to controls,
suggesting that decreased renal clearance is not the primary mechanism
for increased circulating FGF23 in AKI and CKD, although it is recog-
nized that the mechanisms leading to increased plasma FGF23 concen-
tration in AKI may be different than those in CKD.
In cats, plasma FGF23 concentration has been shown to be higher
in hyperphosphatemic cats with azotemic CKD when compared with
normophosphatemic cats at the same IRIS stage.15 Furthermore, cir-
culating FGF23 concentrations have been shown to decrease in cats
with azotemic CKD fed a phosphorous-restricted diet when compared
to controls.15 In addition, increasing phosphorus intake in cats over a
period of 28 weeks led to significantly increased plasma FGF23 con-
centrations without changes in GFR or, initially, plasma PTH concen-
tration and was associated with a decrease in plasma phosphate
concentration.26 Collectively these studies suggest that increased
secretion rather than decreased renal elimination is likely to be
responsible for the increase in plasma FGF23 concentration in early
CKD, indicating that an alteration in phosphate homeostasis may be
present. In our study, the 25th and 75th percentiles for plasma FGF23
concentration in those cats with increased plasma SDMA concentra-
tions were 176 and 523 pg/mL. The distribution of FGF23 concentra-
tions in this group of cats may indicate that only some cats with early
CKD have an alteration in phosphate homeostasis which could sup-
port the diagnostic utility of plasma FGF23 concentration in identify-
ing those cats.
The exact physiological stimuli for FGF23 secretion are not yet fully
understood. In vivo, FGF23 expression is upregulated by phosphate or
1,25 vitamin D37,27 and in vitro extracellular phosphate has been shown to
stimulate FGF23 expression and a variety of genes associated with phos-
phate handling or 1,25 vitamin D3 metabolism in IDG-SW3 osteocyte-like
cells. Whole body phosphate retention because of decreased renal func-
tion may be the direct physiological stimulus for FGF23 secretion.28 Our
results showed no significant correlation between plasma phosphate and
FGF23 concentrations. This has been reported previously in a study of
geriatric non-azotemic cats.12 In humans with normal kidney function, a
correlation between urinary phosphate excretion and tubular reabsorption
but not serum phosphate concentration has been identified.28 A rat model
of early CKD identified increased circulating concentrations of FGF23, nor-
mal serum phosphate concentrations, and increased fractional excretion of
phosphate, but when FGF23 activity was inhibited fractional excretion of
phosphate decreased and serum phosphate concentrations increased,
suggesting that in early CKD, normal plasma phosphate concentrations can
be maintained by the response of functioning nephrons to increased circu-
lating concentrations of FGF23.29
In humans, dietary phosphorus manipulation is an important deter-
minant of serum FGF23 concentration independent of serum phosphate
concentration, sex, age, and serum PTH concentration.30 Interestingly,
chronic excessive consumption of highly available dietary phosphate
may contribute renal injury and development of CKD.31 A recent obser-
vational study of 62 client-owned cats showed a significantly higher die-
tary phosphate and protein content of the food fed before diagnosis in
cats that developed CKD compared to controls.32 No detailed dietary
information was available for the cats in our study, and therefore, the
influence of dietary phosphate on plasma FGF23 concentration or asso-
ciation with early renal dysfunction and increased plasma SDMA con-
centrations could not be determined. Long-term studies evaluating the
effect of excess dietary phosphate on kidney function, plasma SDMA
concentration, plasma FGF23 concentration, and renal handling of phos-
phate are needed to fully understand possible mechanisms of renal
injury and the relationship between plasma FGF23 concentrations and
renal handling of phosphate.
A number of other factors have been associated with circulating
FGF23 concentration. A study of cats with naturally occurring CKD
observed an inverse association between plasma tMg concentration
and FGF23 concentration, and it has been hypothesized that FGF23
has an effect on renal magnesium handling.33 In our study, tMg was
not significantly different between cats with increased SDMA concen-
trations and those with normal SDMA concentrations, and no signifi-
cant correlation was found between plasma FGF23 and tMg
F IGURE 3 Scatter plot illustrating the relationship between
plasma creatinine and plasma fibroblast growth factor 23 (FGF23)
concentration. The broken line represents the upper reference
interval for plasma FGF23 concentration15 (700 pg/mL). Outliers have
been omitted from the graph
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concentrations. However, this association previously has only been
found in azotemic CKD cats. Furthermore, in our study, plasma tMg
concentrations were available for only 5 cats with increased SDMA
concentrations and in 36 cats with plasma SDMA concentrations
within the reference range, which would be considered to have nor-
mal renal function. Total magnesium concentration consists of
protein-bound, complexed, and ionized fractions. Although no consen-
sus exists on whether plasma ionized or tMg measurement best repre-
sents magnesium status, a weak correlation has been found between
ionized and total plasma magnesium concentration, and ionized mag-
nesium status may be overestimated by tMg measurement.34
Serum iron concentration and systemic inflammation also have
been found to have a role in regulation of FGF23.35 In a mouse model
of acute inflammation, a marked increase in FGF23 messenger RNA
expression and inactive cleaved c-terminal FGF23 was observed, but
intact active FGF23 (iFGF23) concentration remained unaltered,
suggesting a role for inflammatory cytokines in regulation of osseous
FGF23 production and cleavage. This finding is particularly interesting
in the context of CKD in cats, where severe dental disease, which is
associated with an inflammation, has been identified as a risk factor
for the development of CKD.36 In human patients, low serum iron
concentrations are associated with high concentrations of iFGF23
independent of markers for inflammation and renal function.37 A
recent study in cats found significantly higher mean serum amyloid A
and hepcidin concentrations and significantly lower mean total iron
concentrations and total iron-binding capacity in cats with CKD com-
pared to healthy controls, suggesting that CKD in cats is associated
with systemic inflammation and altered iron metabolism.38 In our
study, PCV was not significantly different between groups but investi-
gation into iron or inflammatory status was not performed. Future
research including measurement of inflammatory cytokines to charac-
terize the complex relationship among inflammation, iron deficiency
as well as plasma phosphate and FGF23 concentrations in both
healthy cats and those with CKD is indicated.
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One potential limitation of our study is that measurement of plasma
SDMA, PTH, and FGF23 concentrations did not occur for all samples at
the time of sampling. Frozen plasma samples (approximately −80C)
were used for measurement of SDMA, FGF23 and PTH concentrations
within 18 (FGF23 and PTH) or 70 (SDMA) months of the sample date,
leading to the possibility that degradation overtime could affect the mea-
sured concentrations. Symmetric dimethylarginine concentrations have
been shown to be stable over 14 days in canine plasma samples stored
at 4C and analyzed using liquid chromatography mass spectrometry.39
Similarly, the effect of storage time has been studied for PTH and
FGF23, with no effect of storage seen on FGF23 concentrations in feline
plasma stored in EDTA at −20C for 14 days15 and on PTH concentra-
tions in plasma samples stored in EDTA at −80C for a mean of 50 days.
It should be noted however that a now commercially unavailable
immunoradiometric assay was used in this study.40 Stability of SDMA,
FGF23, and PTH in plasma stored at −80C for several years has not
been investigated. However, studies in cats diagnosed with hyperthy-
roidism or CKD, in which FGF23 and PTH concentrations were mea-
sured retrospectively over a similar time frame as the current study,
showed higher plasma FGF23 and PTH concentrations in samples taken
before therapeutic interventions compared to post-intervention samples,
despite the longer storage time of the pre-intervention samples, indicat-
ing that there was minimal effect of storage on measured FGF23 and
PTH concentrations.15,41 Furthermore, in our study, there was no evi-
dence of a negative effect of storage time on plasma concentrations of
FGF23, PTH, and SDMA (data not shown). Therefore, it seems probable
that degradation of FGF23, PTH, and SDMA is not an important factor,
but we cannot exclude the possibility that storage of samples had some
impact in our study.
In conclusion, an early increase in circulating FGF23 has been
reported in humans and cats with CKD. We observed that more cats
with increased plasma SDMA concentration had increased circulating
FGF23 concentrations compared to those with plasma SDMA concen-
trations within the reference range. This finding, together with our
previous observations in geriatric pet cats that plasma FGF23 concen-
tration was predictive of the onset of azotemia,12 suggests that a dis-
turbance in phosphate homeostasis occurs in early stage CKD. Despite
our study's limitations, these observations should be applicable to other
populations of pet cats, having been undertaken on client-owned cats
with naturally occurring CKD. A greater understanding of phosphate
homeostasis and the effect of dietary phosphate restriction in the pre-
azotemic stages of CKD in cats on disease progression and survival
should allow earlier intervention and dietary treatment to be tailored to
the patient's individual requirements. Circulating FGF23 concentration
may have diagnostic utility in identification of those cats that require
phosphate restriction in the non-azotemic stage of CKD and in moni-
toring their response to treatment.
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